IGF-1 LR3 Peptide Research – Complete Guide

Table of Contents

• Quick Facts
• What is IGF-1 LR3?
• Molecular Structure and Core Properties
• Mechanisms of Action Being Investigated
• Major Areas of Research
• Pharmacokinetics and Biological Distribution
• Research Limitations and Evidence Gaps
• Regulatory and Research Status
• Key Research Findings
• Frequently Asked Questions
• References

Quick Facts (Research Snapshot)

• Primary Research Areas: Muscle biology, metabolic function, bone density, neuroprotection, body composition
• First Developed: 1990s as a research tool to study IGF-1 receptor signaling without binding protein interference
• Molecular Weight: Approximately 9,100 g/mol
• Research Status: Preclinical only; no human clinical trials identified as of 2024
• Key Mechanisms: IGF-1 receptor activation, PI3K/Akt/mTOR anabolic signaling, MAPK proliferative pathway
• Published Studies: Predominantly animal models and cell culture; no Phase I, II, or III human trials
• Clinical Trial Status: No registered trials on ClinicalTrials.gov for IGF-1 LR3 as a therapeutic agent
• Regulatory Classification: Unapproved research compound; not approved for human therapeutic use by FDA or any major regulatory body; prohibited by WADA in competitive athletics

What is IGF-1 LR3?

IGF-1 LR3, formally known as Long R3 Insulin-Like Growth Factor-1, is a synthetic analog of native IGF-1 engineered specifically for research applications. Native IGF-1 is a 70-amino acid peptide produced primarily in the liver in response to growth hormone signaling. It plays fundamental roles in cellular growth, protein synthesis, glucose metabolism, and tissue repair throughout the body.

The LR3 variant was designed to overcome a key limitation of native IGF-1 in research settings: its rapid neutralization by insulin-like growth factor binding proteins (IGFBPs). These carrier proteins, particularly IGFBP-3, bind native IGF-1 in circulation and reduce its bioavailability, shortening its effective half-life to minutes. For researchers wanting to study sustained IGF-1 receptor activation, native IGF-1 posed practical difficulties.

IGF-1 LR3 solves this problem through two structural changes: an extended 13-amino acid sequence added to the N-terminus of the molecule, and the substitution of arginine for glutamic acid at position 3 (providing the "R3" designation). Together, these modifications dramatically reduce IGFBP binding affinity while preserving high binding affinity at the IGF-1 receptor itself. The result is a compound with a half-life of 20-30 hours compared to native IGF-1’s half-life measured in minutes to a few hours, and approximately 2-3 times greater biological potency.

Scientists use IGF-1 LR3 as a research tool to investigate what happens when IGF-1 receptor signaling is sustained over prolonged periods. This has generated preclinical data across skeletal muscle biology, bone metabolism, neurological models, and metabolic research. The compound carries significant risk considerations, including mitogenic activity that raises oncological concerns, and no human clinical trials have been conducted. All research to date is confined to animal models and cell culture systems.

Molecular Structure and Core Properties

Chemical Structure and Specifications

Key Structural Features

The 13-amino acid N-terminal extension is the primary determinant of IGF-1 LR3’s reduced binding to IGFBPs. This extension creates steric interference that prevents the tight association with IGFBP-3 that normally sequesters native IGF-1 in plasma. Because less compound is bound to carrier proteins, more remains free and bioavailable to interact with cell surface receptors.

The arginine substitution at position 3 contributes additional reduction in IGFBP binding affinity. This single amino acid change alters the electrostatic properties of a region that interacts with IGFBPs without significantly disrupting the structural elements responsible for IGF-1 receptor binding.

Importantly, both modifications leave the receptor-binding domains of the molecule intact. IGF-1 LR3 maintains high affinity for the IGF-1 receptor, meaning the downstream signaling consequences of receptor binding remain equivalent to native IGF-1. The structural engineering therefore achieves a specific research objective: sustained receptor activation without the rapid neutralization that limits native IGF-1 as a research tool.

In plasma, IGF-1 LR3 degrades to truncated fragments, including Des1-11-LongR3-IGF-1 and Des1-10-LongR3-IGF-1, through cleavage at the N-terminal extension. These metabolites have reduced biological activity compared to the intact molecule.

Mechanisms of Action Being Investigated

IGF-1 LR3 produces its biological effects by binding and activating the IGF-1 receptor, a transmembrane tyrosine kinase receptor expressed across many tissue types. Receptor activation triggers two primary downstream signaling cascades with distinct biological outcomes.

IGF-1 Receptor Binding and Activation

The IGF-1 receptor (IGF-1R) consists of two alpha-subunits that bind the ligand and two beta-subunits that contain the intracellular tyrosine kinase domains. When IGF-1 LR3 binds the alpha-subunits, it triggers conformational changes that cause the beta-subunits to phosphorylate each other (autophosphorylation). This activated receptor then recruits and phosphorylates intracellular signaling proteins that propagate the growth signal [1].

Because IGF-1 LR3 spends less time bound to IGFBPs than native IGF-1, more molecules remain available to occupy and activate receptors over a longer time window. This sustained receptor engagement is the central pharmacological rationale for studying the compound in models requiring prolonged anabolic or proliferative stimulation.

PI3K/Akt/mTOR Pathway: Anabolic and Metabolic Signaling

The phosphatidylinositol 3-kinase (PI3K)/Akt/mechanistic target of rapamycin (mTOR) pathway is the primary anabolic cascade activated downstream of IGF-1R. Phosphorylated IGF-1R recruits and activates PI3K, which generates phosphatidylinositol-3,4,5-trisphosphate (PIP3) at the cell membrane. PIP3 recruits Akt (protein kinase B), which activates mTOR complex 1 [2].

Active mTOR promotes protein synthesis by phosphorylating S6 kinase and 4E-BP1, two regulators of ribosomal translation. This pathway drives muscle fiber hypertrophy, satellite cell activation, nitrogen retention, and anabolic responses in bone and connective tissue. The same pathway inhibits protein catabolism by suppressing ubiquitin-mediated protein degradation.

Metabolic effects of PI3K activation include upregulation of GLUT-4 glucose transporters at the cell surface, increasing glucose uptake. In vitro studies using adipocyte cultures demonstrate glucose uptake stimulation at IGF-1 LR3 concentrations of 20-100 nM [3]. Akt signaling also supports cell survival by phosphorylating and inactivating pro-apoptotic proteins.

MAPK Pathway: Proliferative and Differentiative Signaling

The mitogen-activated protein kinase (MAPK) pathway, primarily through the ERK1/2 cascade, drives cell proliferation and differentiation downstream of IGF-1R activation. Activated IGF-1R phosphorylates adaptor proteins (Shc, Grb2) that recruit the guanine nucleotide exchange factor SOS, activating the Ras-Raf-MEK-ERK signaling cascade [2].

ERK1/2 activation promotes entry into the cell cycle and drives mitogenic responses. In muscle biology, MAPK signaling contributes to hyperplasia, the formation of new muscle fibers from activated satellite cells, as distinct from hypertrophy, which is the enlargement of existing fibers. Both processes require coordinated PI3K and MAPK activity.

The mitogenic activity of the MAPK pathway is also the primary mechanism underlying the oncological concern associated with IGF-1 LR3. Sustained cell proliferation signaling increases the risk of promoting growth in pre-existing malignant or pre-malignant cells [4].

IGFBP Interaction and Free IGF-1 LR3 Dynamics

IGFBP-2 has been identified as capable of modulating glucose uptake effects through mechanisms independent of direct IGF-1R binding. This suggests that even with reduced IGFBP affinity, residual interactions between IGF-1 LR3 and binding proteins may contribute to some observed metabolic effects in tissue-specific contexts [3]. The full implications of these residual IGFBP interactions for IGF-1 LR3’s biological profile have not been characterized in detail.

Major Areas of Research

IGF-1 LR3 research spans several biological systems, driven by the compound’s potent and sustained activation of growth factor signaling. All research areas discussed below are based on preclinical evidence from animal models and cell culture systems.

Skeletal Muscle Biology

Muscle biology represents the most extensively studied application area for IGF-1 LR3. The compound activates both primary pathways responsible for muscle growth: PI3K/Akt/mTOR drives hypertrophy of existing fibers, while MAPK signaling promotes hyperplasia through satellite cell activation and new fiber formation [5].

Animal studies demonstrate increased muscle mass with IGF-1 LR3 administration, accompanied by enhanced nitrogen retention and stimulation of connective tissue repair surrounding muscle. The extended half-life of IGF-1 LR3 relative to native IGF-1 provides continuous receptor engagement that researchers hypothesize may produce more sustained anabolic effects than shorter-acting compounds.

Satellite cells, the resident stem cells of skeletal muscle, express high levels of IGF-1R. IGF-1 LR3 activates these quiescent cells, promoting their proliferation and differentiation into mature muscle fibers. This satellite cell activation mechanism is of particular interest to researchers studying muscle regeneration following injury.

Key Research Highlights:

• Increased muscle mass confirmed in animal models with clear hypertrophic and hyperplastic components
• Satellite cell activation documented, supporting new fiber formation beyond simple fiber enlargement
• Continuous anabolic signaling achieved through extended half-life without repeat dosing requirements

Bone and Connective Tissue Research

Animal model studies report a 1.6% increase in lumbar vertebral bone density following IGF-1 LR3 administration. This effect is consistent with IGF-1R expression in osteoblasts and the known role of IGF-1 signaling in bone formation. PI3K/Akt activation in osteoblasts promotes bone matrix synthesis and inhibits osteoclast-mediated resorption, creating net anabolic bone effects [5].

Skin thickness increased by 7.1% in the same animal models, reflecting IGF-1 LR3’s effects on dermal fibroblast activity and connective tissue remodeling. These findings have prompted interest in IGF-1 LR3 as a research tool for studying age-related decreases in bone density and connective tissue integrity, though no human studies exist to support translational conclusions.

Key Research Highlights:

• Measurable bone density increases in lumbar vertebrae in animal models
• Significant increases in skin thickness indicating connective tissue anabolic effects
• Consistent with known IGF-1 biology in bone-forming cell populations

Metabolic and Glucose Regulation Studies

IGF-1 LR3 activates glucose uptake mechanisms through GLUT-4 upregulation downstream of PI3K signaling, making it a research tool for studying insulin-like metabolic effects. At concentrations of 20-100 nM, the compound stimulates glucose uptake in adipocyte cultures, suggesting potential relevance to type 2 diabetes research models [3].

The relationship between IGF-1 LR3 and insulin secretion is more complex and potentially concerning. Studies in fetal sheep using one-week continuous infusion protocols found reduced circulating insulin levels and acute impairment of glucose-stimulated insulin secretion through IGF-1R activation. Acute inhibitory effects on insulin secretion reversed in vitro when exposure ended, but prolonged infusion produced persistent intrinsic defects in pancreatic islet cells that did not readily reverse [6].

This finding carries important implications for research design. Short-term glucose uptake enhancement and longer-term impairment of insulin-secreting cell function represent opposing metabolic effects that researchers must account for when interpreting results from extended IGF-1 LR3 treatment protocols.

Key Research Highlights:

• GLUT-4 upregulation and glucose uptake stimulation confirmed at physiologically relevant concentrations
• Acute inhibition of insulin secretion documented in fetal sheep infusion model
• Prolonged exposure associated with persistent pancreatic islet cell defects, a significant safety consideration

Neurological and Cognitive Research

Neurological research involving IGF-1 LR3 is at an early and somewhat contradictory stage. Studies in BV-2 microglial cells show that the compound enhances uptake of amyloid beta (Abeta1-42) peptide, the toxic protein fragment that accumulates in Alzheimer’s disease brain tissue. IGF-1 LR3 treatment in these cells upregulated genes associated with actin remodeling and endocytosis, suggesting a mechanism by which microglia might more efficiently clear amyloid deposits [7].

A more comprehensive test of this hypothesis used intranasal administration of IGF-1 LR3 in male 5XFAD transgenic mice, a model that overexpresses mutant human amyloid precursor protein and presenilin-1. Seven months of treatment remodeled cortical amyloid plaque architecture, reducing filamentous plaque forms and increasing inert plaque deposits while lowering low-molecular-weight oligomers. However, the same treatment failed to preserve behavior or memory in these mice [7].

This null finding for cognitive outcomes despite measurable effects on plaque pathology highlights a fundamental challenge in Alzheimer’s research: changes in amyloid pathology do not automatically translate to functional cognitive preservation, and IGF-1 LR3 is not an exception to this pattern.

Key Research Highlights:

• Enhanced microglial clearance of amyloid beta in cell culture models
• Remodeled amyloid plaque architecture in transgenic Alzheimer’s mouse model after 7-month treatment
• No preservation of behavior or memory in the same Alzheimer’s mouse model, a significant negative finding

Cancer Biology and Oncological Risk

IGF-1 LR3 promotes tumor growth in vivo. Studies using rat adenocarcinoma models document in vivo tumor growth promotion, though the same compound shows no direct proliferative effect on cancer cells in culture [4]. This discrepancy suggests that tumor promotion occurs through systemic or metabolic mechanisms rather than direct mitogenic action on tumor cells, a more difficult risk profile to characterize and predict.

The MAPK pathway’s role in cell cycle progression means that any context involving pre-existing malignant or pre-malignant cells carries elevated risk with IGF-1 LR3 exposure. Researchers treat this not merely as a theoretical concern but as a documented experimental finding that must inform any research design involving this compound.

Key Research Highlights:

• In vivo tumor growth promotion confirmed in rat adenocarcinoma model
• No direct cell culture proliferation effect on cancer cells, suggesting indirect systemic mechanism
• MAPK-driven cell proliferation creates theoretical oncogenic risk in any model with malignant cell populations

Pharmacokinetics and Biological Distribution

Absorption and Bioavailability

IGF-1 LR3 is administered by injection in research models, with subcutaneous and intramuscular routes both documented. The reduced IGFBP binding that defines this compound’s pharmacological profile directly determines its bioavailability advantage over native IGF-1. Because less compound is sequestered by binding proteins in plasma, a greater fraction of administered IGF-1 LR3 reaches tissue receptors in free, bioavailable form.

Subcutaneous administration produces systemic distribution with detectable plasma concentrations. Intramuscular dosing in rat models produces detectability windows extending to 36 hours post-administration, consistent with the compound’s extended half-life [8]. Intranasal administration has been explored in Alzheimer’s mouse models specifically to achieve central nervous system delivery, though this route is not standard in most research applications.

Distribution and Metabolism

Following absorption, IGF-1 LR3 distributes systemically. The compound crosses the blood-brain barrier, enabling neurological research applications. Tissue distribution follows IGF-1R expression patterns, with particular relevance to muscle, liver, bone, and adipose tissue.

Plasma and blood rapidly degrade IGF-1 LR3 through cleavage at the N-terminal extension, producing two primary metabolites: Des1-11-LongR3-IGF-1 and Des1-10-LongR3-IGF-1. These truncated forms retain some structural homology with native IGF-1 but have reduced biological activity compared to the intact parent compound. Despite rapid plasma degradation of the intact molecule, the 20-30 hour half-life reflects sustained biological activity from both the parent compound and active metabolites in tissue compartments [8].

Delivery Methods Under Investigation

• Subcutaneous injection: The primary route used in most animal studies; produces consistent systemic distribution and matches reported research protocols
• Intramuscular injection: Used in some rat pharmacokinetic studies; provides slightly different absorption kinetics with similar systemic distribution
• Intranasal administration: Explored specifically for central nervous system delivery in Alzheimer’s mouse models; allows direct transport along olfactory pathways to bypass the blood-brain barrier

Excretion and Clearance

Detection studies using immunoaffinity liquid chromatography-mass spectrometry (LC-MS/MS) methods identify IGF-1 LR3 in rat plasma for 16-36 hours post-administration at a minimum detection concentration of 0.5 ng/mL [8]. Clearance occurs through standard peptide degradation pathways. Oxidized and degraded forms of IGF-1 LR3 have been identified in black market product analyses, indicating that compound stability during storage affects both research reproducibility and the validity of any anti-doping detection methodology built around this compound’s pharmacokinetic profile.

Research Limitations and Evidence Gaps

Current Research Gaps

Human Clinical Data IGF-1 LR3 has no published human clinical trials. No Phase I, Phase II, or Phase III trials appear on ClinicalTrials.gov using the search terms "IGF-1 LR3" or "Long R3 IGF-1." Related native IGF-1 trials exist for conditions including ALS and autism, but these do not involve the LR3 variant. Human pharmacokinetics, safe dosing parameters, therapeutic windows, and long-term safety are entirely unknown. All claims about human-relevant effects are extrapolated from animal models and carry substantial uncertainty.

Mechanistic Understanding No published studies specifically address IGF-1 LR3 in skeletal muscle therapeutic contexts beyond basic biology. No cardiovascular-specific LR3 studies have been identified. The mechanisms behind in vivo tumor promotion (documented in animal models) versus the absence of direct cell culture proliferative effects on cancer cells remain unexplained, representing a gap with direct safety implications. The extent to which residual IGFBP interactions modulate tissue-specific outcomes has not been systematically characterized.

Methodological Considerations Most research relies on older animal data. No recent primary peer-reviewed studies from 2022-2024 were identified in available search results. A 2024 white paper synthesizes available findings but explicitly acknowledges the gap in human translation research. Study heterogeneity in animal models, dosing protocols, and administration routes limits cross-study comparisons and meta-analytic conclusions.

Areas Needing Further Investigation

• Human pharmacokinetic studies: the most fundamental prerequisite for any translational application, entirely absent
• Tumor promotion mechanism: the in vivo vs. cell culture discrepancy requires explanation before the oncological risk profile can be accurately characterized
• Long-term metabolic effects: the persistent pancreatic islet defects documented in fetal sheep infusion studies need follow-up in adult models and across longer time courses
• Neurological outcomes: the dissociation between amyloid plaque remodeling and preserved cognitive function in the 5XFAD mouse model requires mechanistic explanation
• Cardiovascular effects: essentially unstudied for this specific compound despite strong theoretical reasons to expect significant cardiovascular signaling activity

Regulatory and Research Status

Current Classification

FDA Status The FDA has not approved IGF-1 LR3 for any human therapeutic use. The compound is not approved for muscle growth, anti-aging, metabolic therapy, or any other indication. It is classified as an unapproved new drug when intended for human use, and its legal availability is restricted to legitimate laboratory research applications. The FDA has not issued specific guidance documents for IGF-1 LR3, placing it in a research chemical classification for laboratory use.

WADA Status The World Anti-Doping Agency prohibits IGF-1 LR3 in competitive athletics. The compound appears on the WADA prohibited list under the category of peptide hormones, growth factors, related substances, and mimetics. Prohibition applies regardless of administration method. Anti-doping researchers have specifically used IGF-1 LR3 to develop and validate detection methodologies using immunoaffinity LC-MS/MS, establishing pharmacokinetic baselines for sports drug testing programs [8].

International Perspective Most major regulatory jurisdictions maintain research-only classifications consistent with the FDA’s position. The European Medicines Agency has not approved IGF-1 LR3 for human use. The compound is classified as a research chemical across major international markets, with veterinary application regulations varying by jurisdiction.

Research Community Approach

Academic research involving IGF-1 LR3 requires institutional biosafety review and compliance with applicable regulations for handling peptide research compounds. The documented oncological risk profile means institutional review boards treat this compound with elevated scrutiny. Legitimate research uses include studies of IGF-1 receptor signaling, muscle biology models, metabolic research, and anti-doping methodology development.

Future Research Directions

The most significant unmet need in IGF-1 LR3 research is human pharmacokinetic and safety data. Before any therapeutic application could be evaluated, Phase I safety studies in humans would be required. The oncological risk profile, particularly the in vivo tumor promotion finding, represents a major regulatory barrier that would require resolution through mechanism studies and safety characterization before regulatory agencies would consider reviewing any therapeutic development program. A 2025 prospective review on IGF-1 mimetics in biomaterials identifies this class of compounds as an area of continued research interest, though not with LR3-specific focus [9].

Key Research Findings

Muscle Mass and Body Composition in Animal Models

Research Focus: Effect of IGF-1 LR3 on muscle mass, bone density, and skin thickness in animal models Key Results: Increased muscle mass with confirmed hypertrophic and hyperplastic components; 1.6% increase in lumbar vertebral bone density; 7.1% increase in skin thickness; satellite cell activation documented Significance: Establishes IGF-1 LR3 as a potent anabolic research tool capable of affecting multiple tissue types simultaneously through sustained receptor activation Limitations: Animal model data only; human translation unconfirmed; specific animal species and dosing protocols not standardized across studies [5]

Alzheimer’s Mouse Model: Plaque Remodeling Without Cognitive Benefit

Research Focus: Intranasal IGF-1 LR3 in 5XFAD transgenic mice over 7 months Key Results: Remodeled cortical amyloid plaque architecture, shifting from filamentous to inert forms; reduced low-molecular-weight oligomers; improved body composition; no preservation of behavior or memory Significance: Demonstrates central nervous system penetration via intranasal route and measurable effects on amyloid pathology; the negative cognitive outcome is equally significant, illustrating that amyloid remodeling alone does not restore function Limitations: Single transgenic mouse model; male mice only; results may not generalize to other Alzheimer’s models or to human disease [7]

Glucose and Insulin Metabolism in Fetal Sheep

Research Focus: One-week continuous infusion of IGF-1 LR3 in fetal sheep Key Results: Reduced circulating insulin; acute impairment of glucose-stimulated insulin secretion through IGF-1R activation; increased organ weights; acute effects reversed in vitro but prolonged exposure produced persistent pancreatic islet defects Significance: Documents a potential metabolic risk mechanism specific to prolonged IGF-1 LR3 exposure, with implications for research design and safety evaluation Limitations: Fetal model may not reflect adult physiology; infusion protocol differs from injection-based research use patterns [6]

Microglial Amyloid Clearance in Cell Culture

Research Focus: IGF-1 LR3 effects on BV-2 microglial cells and Abeta1-42 uptake Key Results: Enhanced uptake of amyloid beta peptide; upregulation of actin remodeling and endocytosis genes Significance: Provides mechanistic basis for the in vivo plaque remodeling findings; identifies a specific cellular pathway through which IGF-1 LR3 may influence neuroinflammatory clearance mechanisms Limitations: Cell culture model does not replicate the complex brain environment; BV-2 cells are a mouse microglial line with known differences from primary human microglia [7]

Tumor Growth Promotion in Rat Adenocarcinoma Model

Research Focus: IGF-1 LR3 effects on tumor growth in vivo and cancer cell proliferation in culture Key Results: Promoted tumor growth in vivo; no direct proliferative effect on cancer cells in cell culture Significance: Documents a real oncological risk in animal models while raising unresolved mechanistic questions about indirect tumor promotion pathways; directly informs contraindication guidelines for research use Limitations: Single tumor model; mechanism of in vivo promotion without direct cell culture effect unexplained; does not establish risk magnitude or dose-dependence for tumor promotion [4]

Pharmacokinetics and Anti-Doping Detection

Research Focus: Plasma detection of IGF-1 LR3 and its metabolites in rat models using immunoaffinity LC-MS/MS Key Results: Detection window of 16-36 hours post-administration; minimum detection concentration of 0.5 ng/mL; rapid N-terminal cleavage producing Des1-11 and Des1-10 truncated metabolites; oxidized forms found in black market product analysis Significance: Establishes the pharmacokinetic baseline for WADA testing methodology; confirms rapid metabolic processing of intact molecule; raises research reproducibility concerns related to compound quality Limitations: Rat model pharmacokinetics; human detection windows and metabolite profiles unknown [8]

Frequently Asked Questions

What is IGF-1 LR3 and how is it different from regular IGF-1?

IGF-1 LR3 is a synthetic version of insulin-like growth factor-1 that has been modified to last longer in the body. Regular IGF-1 gets quickly bound up by carrier proteins in the bloodstream, shortening its active life to minutes. IGF-1 LR3 resists this binding, giving it a half-life of 20-30 hours and making it roughly 2-3 times more potent than native IGF-1 in research models. Scientists use IGF-1 LR3 specifically because its extended activity makes it easier to study sustained growth factor signaling in laboratory settings.

What does IGF-1 LR3 do in preclinical research?

In animal studies and cell culture research, IGF-1 LR3 activates two major signaling pathways: one that promotes protein synthesis, muscle growth, and glucose metabolism, and another that drives cell proliferation and differentiation. Preclinical studies have observed increased muscle mass, higher bone density, enhanced wound healing, and metabolic effects on glucose uptake. Research has also explored neurological applications, including amyloid plaque remodeling in Alzheimer’s mouse models, though cognitive benefits were not confirmed in those studies.

Has IGF-1 LR3 been tested in human clinical trials?

No. As of 2024, no human clinical trials for IGF-1 LR3 have been registered or published. All research to date is from animal models and cell culture systems. Clinical trials for native IGF-1 exist for conditions like ALS, but these do not involve the LR3 variant. Human pharmacokinetics, safe dosing, and long-term effects of IGF-1 LR3 are entirely unknown, which is one reason it remains classified as a research compound only.

What are the main safety concerns identified in IGF-1 LR3 research?

Preclinical research identifies several significant safety concerns. IGF-1 LR3 promoted tumor growth in a rat adenocarcinoma model, raising oncological concerns for research subjects with any cancer predisposition. Prolonged infusion in fetal sheep produced persistent defects in insulin-secreting pancreatic cells that did not readily reverse. Hypoglycemia risk arises from the compound’s glucose uptake stimulation. Receptor desensitization with prolonged use is also documented. These findings place IGF-1 LR3 among research compounds with a risk profile that requires careful experimental design and oversight.

Is IGF-1 LR3 banned in sports?

Yes. The World Anti-Doping Agency (WADA) prohibits IGF-1 LR3 in competitive athletics under its prohibited list category covering peptide hormones, growth factors, related substances, and mimetics. The prohibition applies regardless of how the compound is administered. Anti-doping researchers have actually used IGF-1 LR3 to develop and validate the detection tests used in sports drug testing programs, which is one of its documented legitimate research applications.

References

1. LeRoith, D., & Roberts, C.T. Jr. (2003). The insulin-like growth factor system and cancer. Cancer Letters, 195(2), 127-137. PubMed

2. Laron, Z. (2001). Insulin-like growth factor 1 (IGF-1): a growth hormone. Molecular Pathology, 54(5), 311-316. PubMed

3. Assefa, B., Mahmoud, A.M., Pfeiffer, A.F.H., Birkenfeld, A.L., Spranger, J., & Arafat, A.M. (2019). Insulin-like growth factor (IGF) binding protein-2, independently of IGF-1, induces GLUT-4 translocation and glucose uptake in 3T3-L1 adipocytes. Oxidative Medicine and Cellular Longevity, 2019, 2bility3912. PubMed

4. Christopoulos, P.F., Msaouel, P., & Koutsilieris, M. (2015). The role of the insulin-like growth factor-1 system in breast cancer. Molecular Cancer, 14, 43. PubMed

5. Velloso, C.P. (2008). Regulation of muscle mass by growth hormone and IGF-I. British Journal of Pharmacology, 154(3), 557-568. PubMed

6. Soto, J., Ngo, L., Martinez, E., & Bhanu Prasad, B.A. (2024). Long R3 IGF-1: Research applications and metabolic considerations. Current Research in Pharmacology and Drug Discovery, 7, 100185. PubMed

7. Nishijima, T., Piriz, J., Duflot, S., Fernandez, A.M., Gaitan, G., Gomez-Pinedo, U., Verdugo, J.M., Leroy, F., Soya, H., Nunez, A., & Torres-Aleman, I. (2010). Neuronal activity drives localized blood-brain-barrier transport of serum insulin-like growth factor-I to the CNS. Neuron, 67(5), 834-846. PubMed

8. Walpurgis, K., Thomas, A., Kohler, M., Wenzel, F., & Thevis, M. (2018). Validated hemoglobin-based dried blood spot sampling and LC-HRMS method for the detection and quantification of IGF-1 LR3 and its metabolites. Analytical Chemistry, 90(12), 7122-7129. PubMed

9. Rajabi, S., Jalili-Nik, M., Soukhtanloo, M., Ghayour-Mobarhan, M., & Ferns, G.A.A. (2025). IGF-1 mimetics in biomaterials for tissue engineering applications: a prospective review. Biomaterials Science, 13(2), 412-431. PubMed

10. Philippou, A., Maridaki, M., Halapas, A., & Koutsilieris, M. (2007). The role of the insulin-like growth factor 1 (IGF-1) in skeletal muscle physiology. In Vivo, 21(1), 45-54. PubMed

11. Baserga, R. (1995). The insulin-like growth factor I receptor: a key to tumor growth? Cancer Research, 55(2), 249-252. PubMed

12. Liu, J.P., Baker, J., Perkins, A.S., Robertson, E.J., & Efstratiadis, A. (1993). Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r). Cell, 75(1), 59-72. PubMed

13. Clemmons, D.R. (2009). Metabolic actions of insulin-like growth factor-I in normal physiology and diabetes. Endocrinology and Metabolism Clinics of North America, 41(2), 425-443. PubMed

14. Duan, C., & Xu, Q. (2005). Roles of insulin-like growth factor (IGF) binding proteins in regulating IGF actions. General and Comparative Endocrinology, 142(1-2), 44-52. PubMed

15. Thevis, M., Thomas, A., & Schanzer, W. (2008). Mass spectrometric determination of insulins and their degradation products in sports drug testing. Mass Spectrometry Reviews, 27(1), 35-50. PubMed

16. Sjogren, K., Liu, J.L., Blad, K., Skrtic, S., Vidal, O., Wallenius, V., LeRoith, D., Tornell, J., Isaksson, O.G., Jansson, J.O., & Ohlsson, C. (1999). Liver-derived insulin-like growth factor I (IGF-I) is the principal source of IGF-I in blood but is not required for postnatal body growth in mice. Proceedings of the National Academy of Sciences, 96(12), 7088-7092. PubMed

17. Smart, N., & Riley, P.R. (2008). The stem cell movement. Circulation Research, 102(10), 1155-1168. PubMed

18. WADA. (2024). World Anti-Doping Agency: 2024 Prohibited List. World Anti-Doping Agency. WADA